STEAP1：前列腺癌治疗的一个有希望的靶点。

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-06-16 DOI:10.1016/j.trecan.2025.05.007

Rohit Singh, Jon Amund Kyte

{"title":"STEAP1：前列腺癌治疗的一个有希望的靶点。","authors":"Rohit Singh, Jon Amund Kyte","doi":"10.1016/j.trecan.2025.05.007","DOIUrl":null,"url":null,"abstract":"The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":17.5000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"STEAP1: a promising target in prostate cancer therapy.\",\"authors\":\"Rohit Singh, Jon Amund Kyte\",\"doi\":\"10.1016/j.trecan.2025.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":17.5000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2025.05.007\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.05.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

前列腺癌（PCa）是一种转移后基本上无法治愈的疾病，其治疗需求尚未得到满足，这突显了开发新疗法的紧迫性。STEAP1（前列腺6跨膜上皮抗原1）是一种细胞表面蛋白，在85%的前列腺肿瘤中高表达，但在正常组织中几乎不存在，这使其成为靶向治疗的有希望的候选蛋白。在这里，我们总结并讨论了强调STEAP1在前列腺癌治疗中有希望作用的最新发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

STEAP1: a promising target in prostate cancer therapy.

The unmet therapeutic need in prostate cancer (PCa), a disease that remains largely incurable after metastasis, underscores the urgency for new treatments. STEAP1 (six transmembrane epithelial antigen of prostate 1) is a cell surface protein highly expressed in >85% prostate tumors but shows little to no presence in normal tissues, making it a promising candidate for targeted therapy. Here, we summarize and discuss recent findings that underscore the promising role of STEAP1 in PCa therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.